Cha2 Ds2 Va Sc Score Calculator

What Is the CHA2DS2-VASc Score?

The CHA2DS2-VASc score is a validated clinical prediction tool that quantifies annual ischemic stroke risk in patients with non-valvular atrial fibrillation (AF). First described by Lip et al. in 2010, the score expanded the earlier CHADS2 model by adding three additional risk modifiers — vascular disease, intermediate age (65–74), and female sex — to improve discrimination between truly low-risk and moderate-risk patients. The acronym encodes each component: Congestive heart failure, Hypertension, Age ≥75 (2 points), Diabetes mellitus, prior Stroke or TIA (2 points), Vascular disease, Age 65–74, and Sex category (female). Scores range from 0 to a maximum of 9 points.

CHA2DS2-VASc Formula and Variable Breakdown

The total score equals the sum of all applicable risk factor points. Each variable is defined precisely to ensure consistent clinical application:

• C — Congestive Heart Failure / LV Dysfunction (1 point): Any documented history of symptomatic CHF or left ventricular ejection fraction (LVEF) below 40%, regardless of current symptom status.
• H — Hypertension (1 point): Resting blood pressure consistently above 140/90 mmHg on two separate readings, or active antihypertensive medication use.
• A2 — Age ≥75 Years (2 points): Advanced age carries the single highest age-related weight in the model, reflecting the steep age-dependent rise in stroke incidence among AF patients.
• D — Diabetes Mellitus (1 point): Fasting plasma glucose exceeding 125 mg/dL, HbA1c ≥6.5%, or active diabetes treatment with insulin or oral hypoglycemic agents.
• S2 — Prior Stroke, TIA, or Systemic Thromboembolism (2 points): A previous cerebrovascular event is the strongest individual predictor in the score and doubles the assigned weight accordingly.
• V — Vascular Disease (1 point): Documented prior myocardial infarction (MI), peripheral artery disease (PAD), or aortic atherosclerotic plaque identified on imaging.
• A — Age 65–74 Years (1 point): Intermediate age category acknowledging elevated but not maximal age-related risk.
• Sc — Sex Category Female (1 point): Biological female sex functions as an independent risk modifier, not a primary driver; a score of 1 derived solely from female sex does not meet the anticoagulation threshold.

Annual Stroke Risk by Score

Validation cohort data published in Lip et al. via PubMed Central (PMC3243195, NIH) and refined in stroke prediction research from the University of Minnesota demonstrate the following approximate annual ischemic stroke rates:

• Score 0 (male) / Score 1 from female sex only: ~0%–0.5% — very low risk; anticoagulation not recommended
• Score 1 (male, non-sex factor): ~1.3% — low-intermediate risk; anticoagulation may be considered individually
• Score 2: ~2.2% — oral anticoagulation recommended
• Score 3: ~3.2% — oral anticoagulation recommended
• Score 4: ~4.0% — oral anticoagulation strongly recommended
• Score 5: ~6.7% — oral anticoagulation strongly recommended
• Score 6: ~9.8% — high risk; anticoagulation strongly indicated
• Score 7–9: ~9.6%–15.2% — very high risk; anticoagulation strongly indicated

Clinical Guidelines and Regulatory Context

The European Society of Cardiology (ESC) 2020 AF guidelines recommend oral anticoagulation for male patients with CHA2DS2-VASc ≥1 and female patients with a score ≥2. The American College of Cardiology (ACC) and American Heart Association (AHA) align closely with these thresholds. Beyond clinical practice, the Centers for Medicare and Medicaid Services (CMS) NCA decision memo on percutaneous left atrial appendage closure references CHA2DS2-VASc thresholds as eligibility criteria, confirming the score's regulatory role in coverage determinations for device-based AF management.

Worked Clinical Example

A 71-year-old female patient presents with hypertension and a prior TIA, but no CHF, diabetes, or vascular disease. Score calculation: Age 65–74 (+1 point, A), Female sex (+1 point, Sc), Hypertension (+1 point, H), Prior TIA (+2 points, S2). Total: 5 points. This score corresponds to approximately 6.7% annual stroke risk. Oral anticoagulation — typically a direct oral anticoagulant (DOAC) such as apixaban or rivaroxaban — is strongly recommended pending individual bleeding risk assessment using tools such as HAS-BLED or ORBIT.

Score Limitations

The CHA2DS2-VASc score applies exclusively to non-valvular atrial fibrillation. Patients with moderate-to-severe mitral stenosis or mechanical prosthetic heart valves require anticoagulation regardless of score. The tool does not incorporate renal function, time in therapeutic range (TTR) for warfarin users, fall risk, or adherence likelihood. Scores should be recalculated at each clinical encounter, particularly when patients cross age thresholds of 65 or 75, or develop new comorbidities such as a TIA, MI, or diabetes diagnosis.